- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03273452
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) (PET)
September 20, 2017 updated by: Hongwei Xue, Qingdao University
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial
This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide for angioimmunoblastic T cell lymphoma patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients enrolled in the trial would be given prednisone, etoposide, thalidomide and Chidamide, and the response and side effects are observed and documented.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hongwei Xue, MD. PhD
- Phone Number: (+86)13475875599
- Email: Xuehongwei1867@163.com
Study Locations
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Recruiting
- The Affiliated Hospital of Qingdao University
-
Contact:
- Hongwei Xue, MD. PhD
- Phone Number: (+86)13475875599
- Email: Xuehongwei1867@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically diagnosed as angioimmunoblastic T cell lymphoma (diagnosed by pathologic department in IIIA hospitals or verified by certified institutions), immunohistochemistry should include: CD3, CD4, CD8, CD20, CD10, CD21, CD35, Bcl6, CXCL13, EBER, PD-1, Ki67.
- At least on measurable focus (≥1.0*1.0cm by imaging), or at least one evaluable focus;
- Age 18-75 years, both male and female;
- ECOG 0-2, KPS≥ 70points;
- Expected survival ≥3 months;
- Peripheral blood neutrophil count ≥1.5×10^9/L, platelet count≥ 75×10^9/L, Hb≥ 90g/L;
- Liver function: bilirubin ≤1.5 times of the normal maximum; AST、ALT≤2 times of the normal maximum (for patients with liver infiltration AST、ALT≤3 times of the normal maximum); renal function: blood creatinine ≤2 times the normal maximum;
- Negative random pregnancy test for fertile women patients within 7 days before enrollment;
- No radiation therapy, chemotherapy, targeted therapy nor hemopoietic stem cell transplantation within 4 weeks before enrollment;
- No anti-tumor therapy at enrollment, including herbal therapy, immunotherapy and biologic therapy, symptomatic treatment is not within this range;
Exclusion Criteria:
- Women during pregnancy or lactation, and fertile women that are not willing to take contraceptive measurements;
- Patients with other malignant tumors simultaneously that have not been effectively controlled;
- Patients with history of using HDAC inhibitors;
- Patients who are allergic to medicine used in the trial, or have metabolic disorders toward these medicine;
- Patients with severe active infection;
- Patients with HIV or syphilis infection;
- Patients with prolonged QT interval (male > 450ms,female > 470ms), or chronic heart failure patients with level III or IV cardiac function; or those have the following heart disease within 6 months before enrollment: acute coronary syndrome, acute heart failure (heart function level III or IV), distinctive ventricular arrhythmias (prolonged ventricular tachycardia, ventricular fibrillation, etc);
- Patients with history of organ transplantation;
- Patients with history of thrombosis and embolism;
- Patients with mental disorders or those who are unable to sign a written consent;
- Patients with drug abuse or long-time alcoholism that may influence the result of the trial;
- Patients who do not have capacity of legal transactions;
- Patients currently in other clinical trials;
- Those who are recognized as inappropriate for the trial by the investigators;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment group
In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
|
Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective remission rate(ORR)
Time Frame: every 3 months until 24 months after the last patient's enrollment
|
the rate of patients who achieve objective remission after the treatment,including CR (complete remission),CRu (complete remission with unrecovered platelet count) and PR (partial remission).
|
every 3 months until 24 months after the last patient's enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
duration of remission
Time Frame: from the day of remission to the date of first documented progression,up to 24 months after the last patient's enrollment
|
from date of complete remission to date of progression, relapse, or death from any cause
|
from the day of remission to the date of first documented progression,up to 24 months after the last patient's enrollment
|
progression free survival
Time Frame: from the day of treatment to the date of first documented progression,up to 24 months after the last patient's enrollment
|
from date of inclusion to date of progression, relapse, or death from any cause
|
from the day of treatment to the date of first documented progression,up to 24 months after the last patient's enrollment
|
overall survival
Time Frame: 24 months after the last patient's enrollment
|
from the date of inclusion to date of death, irrespective of cause
|
24 months after the last patient's enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2017
Primary Completion (Anticipated)
February 1, 2019
Study Completion (Anticipated)
May 1, 2019
Study Registration Dates
First Submitted
August 31, 2017
First Submitted That Met QC Criteria
September 5, 2017
First Posted (Actual)
September 6, 2017
Study Record Updates
Last Update Posted (Actual)
September 25, 2017
Last Update Submitted That Met QC Criteria
September 20, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Xuehw001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
After the trial is finished, all the data would be available at the principle investigator's location.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioimmunoblastic T-cell Lymphoma
-
Navy General Hospital, BeijingChinese PLA General HospitalRecruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaChina
-
The Lymphoma Academic Research OrganisationCelgeneActive, not recruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaFrance, Denmark, United Kingdom, Austria, Belgium
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical GroupRecruitingAngioimmunoblastic T-cell LymphomaChina
-
Sun Yat-sen UniversityNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
Ruijin HospitalActive, not recruitingAngioimmunoblastic T-cell LymphomaChina
-
Peking Union Medical College HospitalBeijing Longfu HospitalNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
University of NebraskaNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell LymphomaUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditionsUnited States
-
Ou Bai, MD/PHDSecond Hospital of Jilin University; China-Japan Union Hospital, Jilin UniversityRecruitingAngioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedChina
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
Clinical Trials on Chidamide
-
Huiqiang HuangUnknownLymphoma, Extranodal NK-T-Cell | EBV
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityUnknown
-
Zhejiang UniversityRecruitingT Lymphoblastic Leukemia/LymphomaChina
-
Sichuan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Liling ZhangCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingNewly Diagnosed Peripheral T-cell LymphomaChina
-
Peking UniversityPeking University International Hospital; Hebei Medical University Fourth HospitalUnknown